InMed Pharmaceuticals (INM) Return on Sales: 2022-2025
Historic Return on Sales for InMed Pharmaceuticals (INM) over the last 3 years, with Sep 2025 value amounting to -1.71%.
- InMed Pharmaceuticals' Return on Sales fell 34.00% to -1.71% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.71%, marking a year-over-year decrease of 34.00%. This contributed to the annual value of -1.65% for FY2025, which is 2.00% up from last year.
- As of Q3 2025, InMed Pharmaceuticals' Return on Sales stood at -1.71%, which was down 3.63% from -1.65% recorded in Q2 2025.
- In the past 5 years, InMed Pharmaceuticals' Return on Sales ranged from a high of -1.08% in Q1 2024 and a low of -10.50% during Q4 2022.
- Moreover, its 3-year median value for Return on Sales was -1.65% (2025), whereas its average is -2.00%.
- Per our database at Business Quant, InMed Pharmaceuticals' Return on Sales skyrocketed by 934bps in 2023 and then slumped by 61bps in 2025.
- Over the past 4 years, InMed Pharmaceuticals' Return on Sales (Quarterly) stood at -10.50% in 2022, then spiked by 934bps to -1.16% in 2023, then slumped by 48bps to -1.64% in 2024, then slumped by 34bps to -1.71% in 2025.
- Its Return on Sales was -1.71% in Q3 2025, compared to -1.65% in Q2 2025 and -1.69% in Q1 2025.